

10/500428

DT04 Rec'd PCT/PTO 28 JUN 2004

PATENT
Attorney Docket No. 229576
Client Reference No. 201213

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

SUGARU et al.

Application No. Unassigned

Filed: June 28, 2004

Art Unit: Unassigned

Examiner: Unassigned

For: REMEDIES FOR CIBOPHOBIA OR
LIFESTYLE-RELATED DISEASES AND
METHOD OF SCREENING THE SAME


SUBMISSION OF SEQUENCE LISTING

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In accordance with the requirements of 37 CFR 1.821-1.825, a sequence listing is being submitted as part of the patent application. The sequence listing is in the form of both a paper copy and a computer readable copy on a computer diskette. The undersigned hereby verifies that the content of the paper copy and the computer readable copy, as concurrently being submitted, are the same.

Respectfully submitted,



John Kilyk, Jr., Reg. No. 30,763
LENDIG, VOIT & MAYER, LTD.
Two Prudential Plaza, Suite 4900
180 North Stetson Avenue
Chicago, Illinois 60601-6780
(312) 616-5600 (telephone)
(312) 616-5700 (facsimile)

Date: June 28, 2004

SEQUENCE LISTING

<110> Sumitomo Pharmaceuticals CO., LTD.

<120> Therapeutic Agent for Anorexia Nervosa or Life-Style Related
Diseases, and Method for Screening Same

<130> 09517

<150> JP 2001-397523

<151> 2001-12-27

<160> 29

<170> PatentIn version 3.1

<210> 1

<211> 1038

<212> RNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(1035)

<400> 1

aug uac aag gac ugc auc gag ucc acu gga gac uau uuu cuu cuc ugu

48

| | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|-----|
| Met | Tyr | Lys | Asp | Cys | Ile | Glu | Ser | Thr | Gly | Asp | Tyr | Phe | Leu | Leu | Cys | | |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | | | |
| gac | gcc | gag | ggg | cca | ugg | ggc | auc | auu | cug | gag | ucc | cug | gcc | aua | cuu | | 96 |
| Asp | Ala | Glu | Gly | Pro | Trp | Gly | Ile | Ile | Leu | Glu | Ser | Leu | Ala | Ile | Leu | | |
| | | 20 | | | | | | 25 | | | | | 30 | | | | |
| ggc | auc | gug | guc | aca | auu | cug | cua | cuc | uua | gca | uuu | cuc | uuc | cuc | aug | | 144 |
| Gly | Ile | Val | Val | Thr | Ile | Leu | Leu | Leu | Leu | Ala | Phe | Leu | Phe | Leu | Met | | |
| | | 35 | | | | | | 40 | | | | | 45 | | | | |
| cga | aag | auc | caa | gac | ugc | agc | cag | ugg | aaU | guc | cuc | ccc | acc | cag | cuc | | 192 |
| Arg | Lys | Ile | Gln | Asp | Cys | Ser | Gln | Trp | Asn | Val | Leu | Pro | Thr | Gln | Leu | | |
| | 50 | | | | | | 55 | | | | 60 | | | | | | |
| cuc | uuc | cuc | cug | agu | guc | cug | ggg | cuc | uuc | gga | cuc | gcu | uuu | gcc | uuc | | 240 |
| Leu | Phe | Leu | Leu | Ser | Val | Leu | Gly | Leu | Phe | Gly | Leu | Ala | Phe | Ala | Phe | | |
| 65 | | | | 70 | | | | | 75 | | | | 80 | | | | |
| auc | auc | gag | cuc | aaU | caa | caa | acu | gcc | ccc | gua | cgc | uac | uuu | cuc | uuu | | 288 |
| Ile | Ile | Glu | Leu | Asn | Gln | Gln | Thr | Ala | Pro | Val | Arg | Tyr | Phe | Leu | Phe | | |
| | | | | 85 | | | | 90 | | | | | 95 | | | | |
| ggg | guu | cuc | uuu | gcu | cuc | ugu | uuc | uca | ugc | cuc | uua | gcu | cau | gcc | ucc | | 336 |
| Gly | Val | Leu | Phe | Ala | Leu | Cys | Phe | Ser | Cys | Leu | Leu | Ala | His | Ala | Ser | | |
| | | 100 | | | | | | 105 | | | | | 110 | | | | |
| aaU | cua | gug | aag | cug | guu | cgg | ggu | ugu | guc | ucc | uuc | ucc | ugg | acg | aca | | 384 |
| Asn | Leu | Val | Lys | Leu | Val | Arg | Gly | Cys | Val | Ser | Phe | Ser | Trp | Thr | Thr | | |
| | | 115 | | | | | | 120 | | | | | 125 | | | | |
| auu | cug | ugc | auu | gcu | auu | ggu | ugc | agu | cug | uug | caa | auc | auu | auu | gcc | | 432 |
| Ile | Leu | Cys | Ile | Ala | Ile | Gly | Cys | Ser | Leu | Leu | Gln | Ile | Ile | Ile | Ala | | |
| | | 130 | | | | | 135 | | | | | | 140 | | | | |
| acu | gag | uau | gug | acu | cuc | auc | aug | acc | aga | ggu | aug | aug | uuu | gug | aaU | | 480 |

| | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
| Thr | Glu | Tyr | Val | Thr | Leu | Ile | Met | Thr | Arg | Gly | Met | Met | Phe | Val | Asn | | |
| 145 | | | | | 150 | | | | | 155 | | | | | 160 | | |
| aug | aca | ccc | ugc | cag | cuc | aaU | gug | gac | uuu | guu | gua | cuc | cug | guc | uau | 528 | |
| Met | Thr | Pro | Cys | Gln | Leu | Asn | Val | Asp | Phe | Val | Val | Leu | Leu | Val | Tyr | | |
| | | | | 165 | | | | | | 170 | | | | | 175 | | |
| guc | cuc | uuc | cug | aug | gcc | cuc | aca | uuc | uuc | guc | ucc | aaa | gcc | acc | uuc | 576 | |
| Val | Leu | Phe | Leu | Met | Ala | Leu | Thr | Phe | Phe | Val | Ser | Lys | Ala | Thr | Phe | | |
| | | | | 180 | | | | | | 185 | | | | | 190 | | |
| ugu | ggc | ccg | ugu | gag | aac | ugg | aag | cag | cau | gga | agg | cuc | auc | uuu | auc | 624 | |
| Cys | Gly | Pro | Cys | Glu | Asn | Trp | Lys | Gln | His | Gly | Arg | Leu | Ile | Phe | Ile | | |
| | | | | 195 | | | | 200 | | | | | | | 205 | | |
| acu | gug | cuc | uuc | ucc | auc | auc | auc | ugg | gug | gug | ugg | auc | ucc | aug | cuc | 672 | |
| Thr | Val | Leu | Phe | Ser | Ile | Ile | Ile | Trp | Val | Val | Trp | Ile | Ser | Met | Leu | | |
| | | | | 210 | | | | 215 | | | | | | | 220 | | |
| cug | aga | ggc | aac | ccg | cag | uuc | cag | cga | cag | ccc | cag | ugg | gac | gac | ccg | 720 | |
| Leu | Arg | Gly | Asn | Pro | Gln | Phe | Gln | Arg | Gln | Pro | Gln | Trp | Asp | Asp | Pro | | |
| 225 | | | | | 230 | | | | | 235 | | | | | 240 | | |
| guc | guc | ugc | auu | gcu | cug | guc | acc | aac | gca | ugg | guu | uuc | cug | cug | cug | 768 | |
| Val | Val | Cys | Ile | Ala | Leu | Val | Thr | Asn | Ala | Trp | Val | Phe | Leu | Leu | Leu | | |
| | | | | 245 | | | | | | 250 | | | | | 255 | | |
| uac | auc | guc | ccu | gag | cuc | ugc | auu | cuc | uac | aga | ucg | ugu | aga | cag | gag | 816 | |
| Tyr | Ile | Val | Pro | Glu | Leu | Cys | Ile | Leu | Tyr | Arg | Ser | Cys | Arg | Gln | Glu | | |
| | | | | 260 | | | | | | 265 | | | | | 270 | | |
| ugc | ccu | uua | caa | ggc | aaU | gcc | ugc | ccc | guc | aca | gcc | uac | caa | cac | agc | 864 | |
| Cys | Pro | Leu | Gln | Gly | Asn | Ala | Cys | Pro | Val | Thr | Ala | Tyr | Gln | His | Ser | | |
| | | | | 275 | | | | 280 | | | | | | | 285 | | |
| uuc | caa | gug | gag | aac | cag | gag | cuc | ucc | aga | gcc | cga | gac | agu | gau | gga | 912 | |

4/24

Phe Gln Val Glu Asn Gln Glu Leu Ser Arg Ala Arg Asp Ser Asp Gly

290

295

300

gcu gag gag gau gua gca uua acu uca uau ggu acu ccc auu cag ccg 960

Ala Glu Glu Asp Val Ala Leu Thr Ser Tyr Gly Thr Pro Ile Gln Pro

305

310

315

320

cag acu guu gau ccc aca caa gag ugu uuc auc cca cag gcu aaa cua 1008

Gln Thr Val Asp Pro Thr Gln Glu Cys Phe Ile Pro Gln Ala Lys Leu

325

330

335

agc ccc cag caa gau gca gga gga gua uaa 1038

Ser Pro Gln Gln Asp Ala Gly Gly Val

340

345

<210> 2

<211> 345

<212> PRT

<213> Homo sapiens

<400> 2

Met Tyr Lys Asp Cys Ile Glu Ser Thr Gly Asp Tyr Phe Leu Leu Cys

1

5

10

15

Asp Ala Glu Gly Pro Trp Gly Ile Ile Leu Glu Ser Leu Ala Ile Leu

20

25

30

Gly Ile Val Val Thr Ile Leu Leu Leu Leu Ala Phe Leu Phe Leu Met

35

40

45

5/24

Arg Lys Ile Gln Asp Cys Ser Gln Trp Asn Val Leu Pro Thr Gln Leu

50

55

60

Leu Phe Leu Leu Ser Val Leu Gly Leu Phe Gly Leu Ala Phe Ala Phe

65

70

75

80

Ile Ile Glu Leu Asn Gln Gln Thr Ala Pro Val Arg Tyr Phe Leu Phe

85

90

95

Gly Val Leu Phe Ala Leu Cys Phe Ser Cys Leu Leu Ala His Ala Ser

100

105

110

Asn Leu Val Lys Leu Val Arg Gly Cys Val Ser Phe Ser Trp Thr Thr

115

120

125

Ile Leu Cys Ile Ala Ile Gly Cys Ser Leu Leu Gln Ile Ile Ile Ala

130

135

140

Thr Glu Tyr Val Thr Leu Ile Met Thr Arg Gly Met Met Phe Val Asn

145

150

155

160

Met Thr Pro Cys Gln Leu Asn Val Asp Phe Val Val Leu Leu Val Tyr

165

170

175

Val Leu Phe Leu Met Ala Leu Thr Phe Phe Val Ser Lys Ala Thr Phe

180

185

190

6/24

Cys Gly Pro Cys Glu Asn Trp Lys Gln His Gly Arg Leu Ile Phe Ile
195 200 205

Thr Val Leu Phe Ser Ile Ile Ile Trp Val Val Trp Ile Ser Met Leu
210 215 220

Leu Arg Gly Asn Pro Gln Phe Gln Arg Gln Pro Gln Trp Asp Asp Pro
225 230 235 240

Val Val Cys Ile Ala Leu Val Thr Asn Ala Trp Val Phe Leu Leu Leu
245 250 255

Tyr Ile Val Pro Glu Leu Cys Ile Leu Tyr Arg Ser Cys Arg Gln Glu
260 265 270

Cys Pro Leu Gln Gly Asn Ala Cys Pro Val Thr Ala Tyr Gln His Ser
275 280 285

Phe Gln Val Glu Asn Gln Glu Leu Ser Arg Ala Arg Asp Ser Asp Gly
290 295 300

Ala Glu Glu Asp Val Ala Leu Thr Ser Tyr Gly Thr Pro Ile Gln Pro
305 310 315 320

Gln Thr Val Asp Pro Thr Gln Glu Cys Phe Ile Pro Gln Ala Lys Leu
325 330 335

7/24

Ser Pro Gln Gln Asp Ala Gly Gly Val

340

345

<210> 3

<211> 1324

<212> RNA

<213> Mus musculus

<220>

<221> CDS

<222> (148).. (1047)

<400> 3

gaggagagau uaaagcaccu gaaguugucu ccuccuuacu cauugcagc cacagcuucc 60

ccaccagcac agccucagag gcuuccggag uagacucgga ggaggagacc agacauccgu 120

ucucgugagg ucuaccuaua agucacc aug uau gag gac ugc gug aag ucc aca 174

Met Tyr Glu Asp Cys Val Lys Ser Thr

1

5

gaa gac uau uac cuc uuc ugu gac aac gag ggg cca ugg gcc auu guu 222

Glu Asp Tyr Tyr Leu Phe Cys Asp Asn Glu Gly Pro Trp Ala Ile Val

10

15

20

25

cug gag ucc uug gca gug auu ggc aua gug guu acc aua uug cua cuc 270

Leu Glu Ser Leu Ala Val Ile Gly Ile Val Val Thr Ile Leu Leu Leu

30

35

40

cug gca uuu cug uuc cuc aug cgg aag guu cag gac ugc agc cag ugg 318

| | |
|---|-----|
| Leu Ala Phe Leu Phe Leu Met Arg Lys Val Gln Asp Cys Ser Gln Trp | |
| 45 50 55 | |
| aac gug cuu ccc acu cag uuc cuc uuc cug cug gcu gug cuc ggg cuc | 366 |
| Asn Val Leu Pro Thr Gln Phe Leu Phe Leu Leu Ala Val Leu Gly Leu | |
| 60 65 70 | |
| uuc gga cuu acu uuu gcc uuc auc auc caa cuc aac cau caa acu gcc | 414 |
| Phe Gly Leu Thr Phe Ala Phe Ile Ile Gln Leu Asn His Gln Thr Ala | |
| 75 80 85 | |
| ccu guu cgc uac uuc cuc uuu ggg guu cuc uuu gcu auc ugc uuc ucc | 462 |
| Pro Val Arg Tyr Phe Leu Phe Gly Val Leu Phe Ala Ile Cys Phe Ser | |
| 90 95 100 105 | |
| ugc cuc cug gcu cau gcc ucc aac cug gug aag cug guc cgg ggu aga | 510 |
| Cys Leu Leu Ala His Ala Ser Asn Leu Val Lys Leu Val Arg Gly Arg | |
| 110 115 120 | |
| guc ucc uuc ugc ugg aca aca auu cug uuc auu gcu auc ggu guc agc | 558 |
| Val Ser Phe Cys Trp Thr Thr Ile Leu Phe Ile Ala Ile Gly Val Ser | |
| 125 130 135 | |
| cug uug cag acc auc auu gcg aua gag uau gug acc cuc auc aug acc | 606 |
| Leu Leu Gln Thr Ile Ile Ala Ile Glu Tyr Val Thr Leu Ile Met Thr | |
| 140 145 150 | |
| aga ggc uug aug uuc gag cau aug aca ccg uau cag cuc aaugug gac | 654 |
| Arg Gly Leu Met Phe Glu His Met Thr Pro Tyr Gln Leu Asn Val Asp | |
| 155 160 165 | |
| uuu guc ugu cuc cug auc uau guc cuc uuc cug aug gcc cuc acu uuc | 702 |
| Phe Val Cys Leu Leu Ile Tyr Val Leu Phe Leu Met Ala Leu Thr Phe | |
| 170 175 180 185 | |
| uuc guc ucc aag gcc acc uuc ugu ggc cca ugu gag aac ugg aaa cag | 750 |

9/24

| | | | |
|---|-----|-----|------|
| Phe Val Ser Lys Ala Thr Phe Cys Gly Pro Cys Glu Asn Trp Lys Gln | | | |
| 190 | 195 | 200 | |
| cac gga agg cuc aua uuu gcu acu gug cug guc ucu auc auu auc ugg | | | 798 |
| His Gly Arg Leu Ile Phe Ala Thr Val Leu Val Ser Ile Ile Ile Trp | | | |
| 205 | 210 | 215 | |
| | | | |
| gug gug ugg auc ucc aug cuc uug aga ggc aac ccc cag cuc cag cga | | | 846 |
| Val Val Trp Ile Ser Met Leu Leu Arg Gly Asn Pro Gln Leu Gln Arg | | | |
| 220 | 225 | 230 | |
| | | | |
| cag ccc cac ugg gac gau gca guc auc ugc auu ggc cug guc acc aac | | | 894 |
| Gln Pro His Trp Asp Asp Ala Val Ile Cys Ile Gly Leu Val Thr Asn | | | |
| 235 | 240 | 245 | |
| | | | |
| gcu ugg guc uuc cug cug auc uac auc auc ccu gag cug agc aua cuc | | | 942 |
| Ala Trp Val Phe Leu Leu Ile Tyr Ile Ile Pro Glu Leu Ser Ile Leu | | | |
| 250 | 255 | 260 | 265 |
| | | | |
| uac agg uca ugu agg cag gag ugu ccu aca caa ggc aac guc ugc cag | | | 990 |
| Tyr Arg Ser Cys Arg Gln Glu Cys Pro Thr Gln Gly Asn Val Cys Gln | | | |
| 270 | 275 | 280 | |
| | | | |
| guc ccu guc uac caa cgc agc uuc agg aug gau acc cag gaa ccc acc | | | 1038 |
| Val Pro Val Tyr Gln Arg Ser Phe Arg Met Asp Thr Gln Glu Pro Thr | | | |
| 285 | 290 | 295 | |
| | | | |
| aga gag ugc ugaucccagc cgaggaguauc ucaucccauc agcuacacua | | | 1087 |
| Arg Glu Cys | | | |

10/24

300

agcccacagc aagaugcagg auuguaaagc uacuggaaac agcauagaga caaccuggaa 1147

gagugcccug cuccacacag ccuaaaagag cccaggggag cacuggacac acugucaaug 1207

aagcauccuu ccuguccuu ccucucuguu ucccugccu uuccacucuu cuggacccag 1267

ccucugaaga cugucauguc cugcacaauu aaaaucuugu ugccaccua aaaaaa 1324

<210> 4

<211> 300

<212> PRT

<213> Mus musculus

<400> 4

Met Tyr Glu Asp Cys Val Lys Ser Thr Glu Asp Tyr Tyr Leu Phe Cys

1 5 10 15

Asp Asn Glu Gly Pro Trp Ala Ile Val Leu Glu Ser Leu Ala Val Ile

20 25 30

Gly Ile Val Val Thr Ile Leu Leu Leu Leu Ala Phe Leu Phe Leu Met

35 40 45

Arg Lys Val Gln Asp Cys Ser Gln Trp Asn Val Leu Pro Thr Gln Phe

50 55 60

11/24

Leu Phe Leu Leu Ala Val Leu Gly Leu Phe Gly Leu Thr Phe Ala Phe
65 70 75 80

Ile Ile Gln Leu Asn His Gln Thr Ala Pro Val Arg Tyr Phe Leu Phe
85 90 95

Gly Val Leu Phe Ala Ile Cys Phe Ser Cys Leu Leu Ala His Ala Ser
100 105 110

Asn Leu Val Lys Leu Val Arg Gly Arg Val Ser Phe Cys Trp Thr Thr
115 120 125

Ile Leu Phe Ile Ala Ile Gly Val Ser Leu Leu Gln Thr Ile Ile Ala
130 135 140

Ile Glu Tyr Val Thr Leu Ile Met Thr Arg Gly Leu Met Phe Glu His
145 150 155 160

Met Thr Pro Tyr Gln Leu Asn Val Asp Phe Val Cys Leu Leu Ile Tyr
165 170 175

Val Leu Phe Leu Met Ala Leu Thr Phe Phe Val Ser Lys Ala Thr Phe
180 185 190

Cys Gly Pro Cys Glu Asn Trp Lys Gln His Gly Arg Leu Ile Phe Ala
195 200 205

12/24

Thr Val Leu Val Ser Ile Ile Ile Trp Val Val Trp Ile Ser Met Leu

210

215

220

Leu Arg Gly Asn Pro Gln Leu Gln Arg Gln Pro His Trp Asp Asp Ala

225

230

235

240

Val Ile Cys Ile Gly Leu Val Thr Asn Ala Trp Val Phe Leu Leu Ile

245

250

255

Tyr Ile Ile Pro Glu Leu Ser Ile Leu Tyr Arg Ser Cys Arg Gln Glu

260

265

270

Cys Pro Thr Gln Gly Asn Val Cys Gln Val Pro Val Tyr Gln Arg Ser

275

280

285

Phe Arg Met Asp Thr Gln Glu Pro Thr Arg Glu Cys

290

295

300

<210> 5

<211> 20

<212> DNA

<213> Artificial/Unknown

<220>

<221> misc_feature

<223> Oligonucleotide designed to act as primer for amplifying GPRC5D mRNA.

<400> 5

acctcttctg tgacaacgag

20

<210> 6

<211> 20

<212> DNA

<213> Artificial/Unknown

<220>

<221> misc_feature

<223> Oligonucleotide designed to act as primer for amplifying GPRC5D mRNA.

<400> 6

ggaagaggac atagatcagg

20

<210> 7

<211> 25

<212> DNA

<213> Artificial/Unknown

<220>

<221> misc_feature

<223> Oligonucleotide designed to act as antisense DNA for inhibiting expression of GPRC5D.

<400> 7

tcatacatgg tgacttatag gtaga

25

<210> 8

<211> 25

<212> DNA

<213> Artificial/Unknown

<220>

<221> misc_feature

<223> Oligonucleotide designed to act as antisense DNA for sequence
resulted from mutation causing abnormal splicing at position 705
of β -globin pre-mRNA in thalassemia.

<400> 8

cctcttacct cagttacaat ttata

25

<210> 9

<211> 25

<212> DNA

<213> Artificial/Unknown

<220>

<221> misc_feature

<223> Oligonucleotide designed to act as primer for amplifying GPRC5D
mRNA.

<400> 9

ggagtatctc atcccatcag ctaca

25

<210> 10

<211> 24

<212> DNA

<213> Artificial/Unknown

<220>

<221> misc_feature

<223> Oligonucleotide designed to act as primer for amplifying GPRC5D mRNA.

<400> 10

cactcttcca ggttgctct atgc

24

<210> 11

<211> 22

<212> DNA

<213> Artificial/Unknown

<220>

<221> misc_feature

<223> Oligonucleotide designed to act as primer for amplifying GAPDH mRNA.

<400> 11

caagagaggc cctatcccaa ct

22

<210> 12

<211> 23

<212> DNA

<213> Artificial/Unknown

<220>

<221> misc_feature

<223> Oligonucleotide designed to act as primer for amplifying GAPDH mRNA.

<400> 12

ctaggcccct cctgttatta tgg

23

<210> 13

<211> 20

<212> DNA

<213> Artificial

<220>

<221> misc_feature

<223> Oligonucleotide designed to act as sense primer for amplifying human G protein Gα16 cDNA fragment containing full length ORF.

<400> 13

ccatggcccg ctcgctgacc

20

<210> 14

<211> 21

<212> DNA

<213> Artificial

<220>

<221> misc_feature

<223> Oligonucleotide designed to act as antisense primer for
amplifying human G protein Gα16 cDNA fragment containing full
length ORF.

<400> 14

ccgaggctgg agagatagac c

21

<210> 15

<211> 19

<212> DNA

<213> Artificial

<220>

<221> misc_feature

<223> Oligonucleotide designed to act as sense primer for amplifying
human G protein Gαi2 cDNA fragment containing full length ORF.

<400> 15

gcggcgggagc ggcggaacg

19

<210> 16

<211> 24

<212> DNA

<213> Artificial

<220>

<221> misc_feature

<223> Oligonucleotide designed to act as antisense primer for
amplifying human G protein G α i2 cDNA fragment containing full
length ORF.

<400> 16

ggagaaaagc ggcgggggaa cagg

24

<210> 17

<211> 21

<212> DNA

<213> Artificial

<220>

<221> misc_feature

<223> Oligonucleotide designed to act as sense primer for amplifying
human G protein G α S2 cDNA fragment containing full length ORF.

<400> 17

ccatgggctg cctcggaac a

21

<210> 18

<211> 23

<212> DNA

<213> Artificial

<220>

<221> misc_feature

<223> Oligonucleotide designed to act as antisense primer for
amplifying human G protein GαS2 cDNA fragment containng full
length ORF.

<400> 18

ggtttcgcaa aatcactcgg ggg

23

<210> 19

<211> 21

<212> DNA

<213> Artificial

<220>

<221> misc_feature

<223> Oligonucleotide designed to act as sense primer for amplifying
human G protein Gα16 cDNA fragment from initiation codon.

<400> 19

atggcccgct cgctgacctg g

21

<210> 20

<211> 21

<212> DNA

<213> Artificial

<220>

<221> misc_feature

<223> Oligonucleotide designed to act as sense primer for amplifying
human G protein G α i2 cDNA fragment from initiation codon.

<400> 20

atgggctgca ccgtgagcgc c

21

<210> 21

<211> 20

<212> DNA

<213> Artificial

<220>

<221> misc_feature

<223> Oligonucleotide designed to act as sense primer for amplifying
human G protein G α S2 cDNA fragment from initiation codon.

<400> 21

atgggctgcc tcgggaacag

20

<210> 22

<211> 18

<212> DNA

<213> Artificial

<220>

<221> misc_feature

<223> Oligonucleotide designed to act as antisense primer for
amplifying multiple cloning site of plasmid pcDNA3.1(+).

<400> 22

tagaaggcac agtcgagg

18

<210> 23

<211> 24

<212> DNA

<213> Artificial

<220>

<221> misc_feature

<223> Sense strand oligonucleotide designed to construct linker
containing nucleotide sequence encoding 6xHis-tag peptide
sequence.

<400> 23

gatatccatc atcatcatca ccat

24

<210> 24

<211> 18

<212> DNA

<213> Artificial

<220>

<221> misc_feature

<223> Antisense strand oligonucleotide desined to construct linker
containing nucleotide sequence encoding 6xHis-tag peptide
sequence.

<400> 24

atggtgatga tgatgatg

18

<210> 25

<211> 20

<212> DNA

<213> Artificial

<220>

<221> misc_feature

<223> Oligonucleotide designed to act as sence primer for amplifying
GPRC5D cDNA.

<400> 25

ggagaagggc atcagaaaac

20

<210> 26

<211> 22

<212> DNA

<213> Artificial

<220>

<221> misc_feature

<223> Oligonucleotide designed to act as antisense primer for
amplifying GPRC5D cDNA.

<400> 26

ttataactcct cctgcatctt gc

22

<210> 27

<211> 58

<212> DNA

<213> Artificial

<220>

<221> misc_feature

<223> Oligonucleotide designed to act as sense primer for
amplifying ORF of GPRC5D cDNA.

<400> 27

ggggacaagt ttgtacaaaa aagcaggctc caccatgtac aaggactgca tcgagtc

58

<210> 28

<211> 55

<212> DNA

<213> Artificial

<220>

<221> misc_feature

<223> Oligonucleotide designed to act as antisense primer for
amplifying ORF (R form) of GPRC5D cDNA.

<400> 28

ggggaccact ttgtacaaga aagctgggtc attatactcc tcctgcatct tgctg 55

<210> 29

<211> 51

<212> DNA

<213> Artificial

<220>

<221> misc_feature

<223> Oligonucleotide designed to act as antisense primer for
amplifying ORF (F form) of GPRC5D cDNA.

<400> 29

ggggaccact ttgtacaaga aagctgggtc tactcctcct gcatcttgct g 51